| Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. | |
| | |
MedLine Citation:
|
PMID: 10672894 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Reports of corticosteroid-induced adverse psychiatric effects began to appear in the literature soon after the introduction of these medications in the 1950s. Unfortunately, early studies relied on informal classification and measurement procedures and tended to utilise nonspecific descriptive terminology (such as steroid psychosis'). A growing number of contemporary investigations have begun to address these problems. However, the literature remains surprisingly undeveloped from a pharmacoepidemiological perspective, consisting largely of case reports and case series. The objective of this review is to summarise published data concerning corticosteroid-induced adverse psychiatric effects. A clinical perspective will be adopted since opportunities to minimise the impact of corticosteroid-induced adverse effects tend to present themselves most readily within the sphere of clinical management. Some of the psychiatric adverse effects of corticosteroids are mild, and not necessarily clinically significant. However, several serious psychiatric syndromes can be caused by corticosteroids: substance-induced mood disorders (with depressive, manic and mixed features), substance-induced psychotic disorders and delirium. While certain clinical groups may be at greater risk of corticosteroid-induced adverse psychiatric effects, corticosteroid-induced psychiatric toxicity is remarkably unpredictable. The literature regarding prevention and treatment of corticosteroid-induced adverse psychiatric effects is poorly developed. As a result, the emphasis of this review is on clinical and epidemiological evidence linking specific adverse effects to corticosteroid medications. However, clinical reports do provide some practical guidance for prevention and treatment, and these are summarised as well. A variety of pharmacological strategies for treatment and prevention have been proposed. Education and support also appear to be important, and perhaps neglected. |
| | |
Authors:
|
S B Patten; C I Neutel |
Related Documents
:
|
22767304 - Myopericarditis during a primary epstein-barr virus infection in an otherwise young adu... 1764854 - Gliomatosis cerebri: a case report. 16859554 - Postictal psychosis: presymptomatic risk factors and the need for further investigation... 22773274 - Postmortem biochemical investigations in hypothermia fatalities. 1666964 - Untreated hypophosphatemic vitamin d-resistant rickets with symptomatic ossification of... 3278084 - Kasabach-merritt syndrome. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drug safety : an international journal of medical toxicology and drug experience Volume: 22 ISSN: 0114-5916 ISO Abbreviation: Drug Saf Publication Date: 2000 Feb |
Date Detail:
|
Created Date: 2000-02-25 Completed Date: 2000-02-25 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9002928 Medline TA: Drug Saf Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 111-22 Citation Subset: IM |
Affiliation:
|
Department of Community Health Sciences, Faculty of Medicine, The University of Calgary, Alberta, Canada. patten@ucalgary.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
administration & dosage,
adverse effects* Humans Psychoses, Substance-Induced / diagnosis, epidemiology, etiology*, therapy Substance Withdrawal Syndrome / etiology* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patient-oriented strategies for the prevention of drug interactions.
Next Document: Utility of acetylcysteine in treating poisonings and adverse drug reactions.